Biotech Co.*

Pharma Co.


Terms/Details (Date)


Pfizer Inc.

Abraxis is buying Pfizer's Cruce Davila manufacturing facility in Puerto Rico

They entered a definitive agreement on the deal, terms of which were not disclosed (4/25)

Affymax Inc.*

American Peptide Co. Inc.

Deal for the manufacture of Affymax's Hematide

The synthetic, peptide-based erythro- poiesis-stimulating agent is in Phase II trials; terms were not disclosed (4/5)

BioviRx Inc.*

IDT GmbH (Germany; unit of the Klocke Group)

Deal under which IDT will manufacture the oral rotavirus vaccine RotaShield for BioviRx

BioviRx plans to reintroduce the vaccine to the market after a re-analysis of data; it was approved in 1998 but taken off the market in 1999 (3/27)

Chiron Corp (CHIR)

Schering AG (Germany)

Schering said it will exercise its option to buy or lease all assets used by Chiron in the manufacture of Betaseron

The deal covering the interferon beta-1b product was subject to the closing of the acquisition of Chiron by Novartis AG; the price will be determined (2/24)

Systems Inc.
(Canada; TSE:CHR)

AppTec Laboratory Services Inc.

Deal for the scale-up and manufacture of Chromos' monoclonal antibody candidate CHR-1103

AppTec will manufacture product for pre- clinical and Phase I studies; the product is being developed for multiple sclerosis; terms were not disclosed (4/6)


GE Healthcare

GE will provide production reagents for use in the manufacture of vaccines and compounds by CytoGenix

CytoGenix will be GE's exclusive customer for re-agents where the intended application is the manufacture of therapeutic compounds using CytoGenix's processes (3/23)


Diosynth Biotechnology (unit of NV Organon)

Deal under which Diosynth will manufacture the recombinant antigen component of Dendreon's Provenge

Provenge is a cellular immunotherapy product being studied for prostate cancer; the deal reflects a continuing collaboration between the companies (3/2)


Astellas Pharma Inc. (Japan)

Astellas acquired Dynogen's North Carolina- based research facility

The facility specializes in preclinical studies for genitourinary disorders; terms were not disclosed (3/1)

Medi-Tech Inc.
(Canada; FMTI)

Chusei Oil Co. Ltd. (Japan)

Chusei purchased Forbes' interest in their 50-50 Phyto-Source LP sterol manufacturing joint venture

Forbes gets a $25M payment; they also entered an agreement that will ensure Forbes a supply of Reducol and other wood sterols for five years (2/23)

GNI Ltd.*

Beijing Continent Pharmaceutical Co. Ltd. (China)

GNI took a stake in BCP as part of a strategic alliance

The deal gives GNI access to BCP's manufacturing facilities, sales force and sales distribution network (4/11)

Genetics Inc.

Access Business Group International LLC (subsidiary of Alticor Inc.)

An Alticor subsidiary got rights to market two genetic tests, one for heart health and one covering general nutrition

The test will be marketed exclusively through Alticor subsidiary Quixtar, under Quixtar's Gensona brand (2/28)


F. Hoffmann- La Roche Ltd. (Switzerland)

Martek will help Roche in the production of shikimic acid

Shikimic acid is the starting material used to produce Roche's Tamiflu; terms were not disclosed (3/16)

Nabi Bio-

Sanofi Pasteur (France)

Nabi will help in the manufacture of the rabies product Imogam Rabies-HT

Nabi will fractionate human plasma used for the production of the immune globulin product; terms were not disclosed (4/26)

Novavax Inc.

PacificGMP LLC

Deal to develop a commercial-scale production process for Novavax's pandemic influenza

The deal centers on Novavax's H5N1 avian influenza vaccine, based on its virus-like particle technology (2/28)

SciGen Ltd.

Shreya Group (India)

Deal under which SciGen would acquire Shreya's manufacturing facility in India

Shreya previously was SciGen's contract manufacturer for biotechnology-derived products; terms were not disclosed (4/5)

Genetics Inc.

Laureate Pharma Inc.

Deal for the manufacture of Seattle Genetics' SGN-33 and SGN-70 humanized monoclonal antibody product candidates

Laureate Pharma will perform scale-up and manufacturing of clinical trial materials for both programs; terms were not disclosed (4/25)


Novo Nordisk
A/S (Denmark)

Celliance Corp. got rights to distribute Novo's recombinant human insulin in the cell culture market

Celliance is a Serologicals subsidiary; terms of the expanded four-year supply agreement were not disclosed (3/16)

Sinovac Biotech

LG Life Sciences Ltd. (South Korea)

Sinovac will act as exclusive distributor for LGLS' hepatitis B vaccine in China

Terms of the deal were not disclosed (3/13)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.